Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C29H35N3O4.C4H4O4 |
| Molecular Weight | 605.6781 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 1 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(=O)\C=C\C(O)=O.CNC(=O)C1=CC2=C(C=CN2C3CCN(CCC4=C5OC(C)(C)CC(=O)C5=CC=C4OC)CC3)C=C1
InChI
InChIKey=MNUJXFRXXTZIIO-WLHGVMLRSA-N
InChI=1S/C29H35N3O4.C4H4O4/c1-29(2)18-25(33)22-7-8-26(35-4)23(27(22)36-29)12-15-31-13-10-21(11-14-31)32-16-9-19-5-6-20(17-24(19)32)28(34)30-3;5-3(6)1-2-4(7)8/h5-9,16-17,21H,10-15,18H2,1-4H3,(H,30,34);1-2H,(H,5,6)(H,7,8)/b;2-1+
| Molecular Formula | C29H35N3O4 |
| Molecular Weight | 489.6059 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C4H4O4 |
| Molecular Weight | 116.0722 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 1 |
| Optical Activity | NONE |
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Tue Apr 01 16:51:28 GMT 2025
by
admin
on
Tue Apr 01 16:51:28 GMT 2025
|
| Record UNII |
DN9H25S82Z
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Code | English | ||
|
Preferred Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
915024-75-8
Created by
admin on Tue Apr 01 16:51:28 GMT 2025 , Edited by admin on Tue Apr 01 16:51:28 GMT 2025
|
PRIMARY | |||
|
DN9H25S82Z
Created by
admin on Tue Apr 01 16:51:28 GMT 2025 , Edited by admin on Tue Apr 01 16:51:28 GMT 2025
|
PRIMARY | |||
|
16038980
Created by
admin on Tue Apr 01 16:51:28 GMT 2025 , Edited by admin on Tue Apr 01 16:51:28 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
Bottom Line: The plasma concentrations inducing 50% RO (EC50) estimated by both direct and effect compartment models were in good agreement.Dose-dependent therapeutic effects of E2110 on dysregulated micturition in different rat models of pollakiuria were also consistently explained by achievement of 5-HT1A RO by E2110 in a certain range ( 60%).Plasma drug concentrations inducing this RO range and EC50 would accordingly be objective indices in comparing pharmacokinetics-RO relationships between rats and humans.
|